Researchers at the Instituto de Salud Carlos III (ISCIII) published a study in Stem Cells Research & Therapy evaluating non-animal hydrogels for the synthesis of human lung organoids. The findings reveal that alternatives like Biogelx, PLTMax, and GelMA fail to match the structural maturity and efficacy of traditional animal-derived Matrigel, highlighting ongoing biocompatibility challenges in regenerative medicine.
The Scaffold Dilemma in Organoid Engineering
Generating laboratory-grown organoids requires more than just human pluripotent stem cells; it demands a precise extracellular matrix. Researchers rely on inert chemical or biological substrates known as hydrogels to provide the structural support necessary for cellular differentiation. Without a stable matrix, stem cells cannot properly organize into functional, three-dimensional tissues that mimic real organ activity.
One of the most used hydrogels for this purpose is Matrigel. While it successfully drives tissue development, its animal origins create a bottleneck for clinical translation and human-centric testing. Investigators have pushed to replace it with synthetic or non-animal alternatives to be biocompatible with the development of minilungs in the human context.
Testing Non-Animal Alternatives: Biogelx, PLTMax, and GelMA
To overcome the limitations of animal-derived substrates, a team including Irene Chamorro-Herrero from the Stem Cell and Organoid Biotechnology Laboratory at the ISCIII’s Chronic Diseases Research Unit (UFIEC), alongside Julio Sempere from the National Center for Microbiology (CNM) and CIBERES, put three distinct non-animal hydrogels to the test.
The evaluation focused on Biogelx, PLTMax, and GelMA. The core objective was determining whether these compounds could guide human pluripotent stem cells toward mature lung organoids just as effectively as Matrigel.
The results showed that the organoids cultured using these alternative hydrogels displayed structural aberrations and lacked sufficient biological maturity.
The authors explicitly concluded that the tested hydrogels “no han demostrado la misma capacidad que ‘Matrigel’.”
Future Directions for Synthetic Bioprinting
Despite the results with Biogelx, PLTMax, and GelMA, the study yields empirical data for the field of regenerative medicine. The experimental process has mapped out new pathways for screening synthetic and human-derived substrates.
The research team emphasized that the generated data will facilitate the ongoing search for optimal materials to drive in vitro bioprinting. Finding a viable alternative remains a priority for developing lab-grown tissues that can eventually serve as alternatives for the replacement of tissues and organs.
For now, the bio-engineering community must continue to engineer synthetic matrices capable of matching the biochemical cues of animal-derived substrates without compromising structural integrity.
